Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer

By afschroeder • May 31, 2026

Brown LG, Coleman IM, Chu TLH, Sayar E, Patel RA, Hanratty B, Adil M, Li D, Li Y, Nguyen HM, Sessions CJ, Sweeney EL, Alumkal JJ, da Costa RMG, Wang Y, Lin DW, True LD, Dumpit R, Corey E, Lee JK, Nelson PS, Xin L, Haffner MC, Morrissey C. Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer. Neoplasia. 2026 May 30;78:101321. doi: 10.1016/j.neo.2026.101321. Epub ahead of print. PMID: 42217442.

Tags: Hematology/Oncology, Neuroendocrine, prostate, Publications, RBFOX2, TEAD1, YAP

Related Posts

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono[...]

Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study

Nolin A, Brown MD, Thomas SM, Strickland KC, Bean S, Neff JL, Pothuri B, Moore KN, Mullen M, Clark LH, Konecny G, Jackson AL, Ko[...]

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia

Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld[...]